Related Experiment Video
Updated: Sep 21, 2025
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Stereotactic radiofrequency ablation as a valid first-line treatment option for hepatocellular adenomas
Gregor Laimer1, Peter Schullian1, Yannick Scharll1
1Interventional Oncology-Microinvasive Therapy (SIP), Department of Radiology, Medical University Innsbruck, Innsbruck, Austria.
Objectives:
This study aimed to assess the safety and efficacy of stereotactic radiofrequency ablation (SRFA) in patients with hepatocellular adenomas (HCA).
Methods:
Retrospective analyses of all patients referred for SRFA treatment at our institution between January 2010 and October 2020 revealed 14 patients (10 women; mean age 34.4 [range, 17-73 years]) with 38 HCAs treated through 18 ablation sessions. Ablations were considered successful if a safety margin >5 mm was achieved. Demographic, interventional, and outcome data were collected and analyzed. Primary and secondary technical efficacy rates were assessed based on follow-up images consisting of contrast-enhanced CT or MR scans.
Results:
The mean tumor size was 22 mm (range, 7-75 mm). Overall, 37/38 (97.4%) tumors were successfully ablated at the initial SRFA (primary efficacy rate of 97.4%). The median follow-up duration was 49.6 months. No deaths or adenoma-related complications (hemorrhage or malignant transformation) were observed. Disease-free survival rates at 1, 3, and 5 years from the date of the first SRFA were 100%, 85.8%, and 85.8%, respectively. Two patients developed new distant tumors retreated with consecutive re-ablation. No major complications occurred during any of the 18 ablation sessions.
Conclusions:
Percutaneous thermal ablation is efficient in the treatment of HCAs and may thus be considered a valid first-line treatment option. In addition, SRFA allows for an effective, minimally invasive treatment of large and multiple hepatic tumors within one session.
Insights
Stereotactic radiofrequency ablation (SRFA) effectively treats hepatocellular adenomas (HCAs), achieving a 97.4% initial success rate with no major complications. This minimally invasive approach is a viable first-line option for hepatic tumors.
Area of Science:
- Hepatology
- Interventional Radiology
- Oncology
Background:
- Hepatocellular adenomas (HCAs) are benign liver tumors that can pose risks of hemorrhage and malignant transformation.
- Treatment options for HCAs include surgical resection and minimally invasive techniques.
Purpose of the Study:
- To evaluate the safety and efficacy of stereotactic radiofrequency ablation (SRFA) for treating hepatocellular adenomas (HCAs).
Main Methods:
- Retrospective analysis of 14 patients with 38 HCAs treated with SRFA between 2010 and 2020.
- Success defined by a >5 mm safety margin; efficacy assessed via contrast-enhanced CT/MR scans.
Main Results:
- 97.4% of HCAs were successfully ablated initially.
- No deaths or adenoma-related complications (hemorrhage, malignant transformation) were observed.
- Disease-free survival rates at 1, 3, and 5 years were 100%, 85.8%, and 85.8% respectively.
Conclusions:
- Percutaneous thermal ablation, specifically SRFA, is an efficient and safe first-line treatment for HCAs.
- SRFA offers effective, minimally invasive treatment for large and multiple hepatic tumors in a single session.
More Related Videos
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018